Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6838090 | 0.92 | EPHA2 (0.34) | SLC6A2SLC6A4EPHA2KDRSYK | |
| SCHEMBL6840135 | 0.92 | JAK1 (0.31) | SLC6A2SLC6A4EPHA2SYK | |
| SCHEMBL6837700 | 0.87 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3EPHA2SSTR4 | |
| SCHEMBL6838709 | 0.86 | CCR3 (0.33) | SLC6A4 | |
| SCHEMBL6837740 | 0.86 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3EPHA2SSTR4 | |
| SCHEMBL6838494 | 0.85 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3EPHA2SSTR4 | |
| SCHEMBL6838669 | 0.84 | SSTR4 (0.37) | SLC6A2SLC6A4SLC6A3SSTR4GRIN1 | |
| SCHEMBL6838620 | 0.83 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3EPHA2SSTR4 | |
| SCHEMBL6838725 | 0.83 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3EPHA2SSTR4 | |
| SCHEMBL6840144 | 0.82 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1256582-A1 | 1H-IMIDAZOPYRIDINE DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | IL2, IL1A, IL4 | SLC6A2 4336/4885SLC6A4 3973/4885SLC6A3 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.